Clinical trial

Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs

Name
NIMAO/2017-01/ECN-01
Description
The numerical ratio between the value of the thrombin generation test performed without soluble thrombomodulin and the value of the thrombin generation test performed in the presence of soluble thrombomodulin, performed pre-surgically, could predict the risk of early venous thromboembolism after placement of total hip or knee prosthesis.
Trial arms
Trial start
2019-02-21
Estimated PCD
2023-02-20
Trial end
2023-10-17
Status
Completed
Phase
Early phase I
Treatment
Blood test
Additional blood test of 4,5 ml of venous blood
Arms:
interventional group
Doppler ultrasound
Vascular ultrasonic vascular exploration of the lower limbs
Arms:
interventional group
Size
146
Primary endpoint
Estimate the numerical ratio between the value of the thrombin generation test performed without soluble thrombomodulin and the value of the thrombin generation test performed in the presence of soluble thrombomodulin
Day 0
Occurrence of Symptomatic pulmonary embolism
Day 7 (± 2)
Occurrence of Symptomatic deep vein thrombosis somewhere in the body
Day 7 (± 2)
Occurrence of Symptomatic deep vein thrombosis in legs
Day 7 (± 2)
Eligibility criteria
Inclusion Criteria: * The patient must have his consent and signed the consent form. * The patient must affiliated or a beneficiary of a health insurance plan. * The patient is at least 18 years old * Patient with an indication of total hip prosthesis or total knee replacement surgery set unilateral Exclusion Criteria: * The patient is participating in another interventional study. * The patient is in an exclusion period determined by a previous study. * Minor patients, people in emergency situations. * The patient is under the protection of justice, guardianship or curatorship. * The patient refuses to sign the consent. * It is not possible to inform the patient. * The patient is pregnant, parturient, or breastfeeding. * The patient has a contraindication (or incompatible drug combination) to drug thromboprophylaxis applied according to good clinical practice and recommendations of learned societies * Long-term anticoagulant therapy for personal thrombotic history. * Known hemorrhagic disease. * Haemorrhagic risk perceived during the consultation of preoperative anesthesia, leading to modify / develop the usual thromboprophylaxis. * Chronic liver disease. * Chronic renal failure with calculated clearance \<30 ml / min. * Extreme body mass index: \<18 kg.m-2 or\> 40 kg.m-2 * total hip prosthesis or total knee prosthesis in the immediate aftermath of a bone fracture. * total hip prosthesis resumption. * Installation of more than one joint prosthesis. * Surgery in the previous 3 months. * Infective push in the previous 3 months. * Indication of haemostatic treatment for abnormal haemorrhagic risk. * Severe impairment of renal function with a calculated clearance \<30 ml / min. * Contraindication (allergic, metabolic, other ...) to usual drug thromboprophylaxis. * Condition requiring dosage adjustment of drug thromboprophylaxis. * Indication to put in place intermittent pneumatic compression for perioperative thromboprophylaxis.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 146, 'type': 'ACTUAL'}}
Updated at
2023-11-18

1 organization

1 product

3 indications

Product
Blood test
Indication
Hip Replacement
Indication
Knee Prosthesis